Matt discusses the need for a reevaluation of FDA's approach to clinical trials in the aging space, emphasizing the importance of appropriate endpoints and acceptable levels of risk. He highlights the challenge of evaluating risk-reward and urges society to take a realistic look at normal aging and the potential for intervention.
